PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer.

Abstract The use of prophylactic cranial irradiation (PCI) to treat brain metastases (BM) in non-small cell lung cancer (NSCLC) is restricted due to the potential associated toxicity and lack of survival benefit. BM can have a negative impact on neurocognitive function (NF) and quality of life (QOL). The aim of this review was to assess the impact of PCI on disease-specific and NF and QOL outcomes.
PMID
Related Publications

A systematic review of risk factors for brain metastases and value of prophylactic cranial irradiation in non-small cell lung cancer.

Prophylactic cranial irradiation in locally advanced non-small cell lung cancer: outcome of recursive partitioning analysis group 1 patients.

Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review.

Patient preferences regarding prophylactic cranial irradiation: A discrete choice experiment.

Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.

Authors

Mayor MeshTerms

Cranial Irradiation

Keywords

Prophylactic cranial irradiation

disease-free survival

neurocognitive function

non-small cell lung cancer

overall survival

quality of life

review

Journal Title anticancer research
Publication Year Start




PMID- 29277750
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180101
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer.
PG  - 7-14
AB  - BACKGROUND: The use of prophylactic cranial irradiation (PCI) to treat brain
      metastases (BM) in non-small cell lung cancer (NSCLC) is restricted due to the
      potential associated toxicity and lack of survival benefit. BM can have a
      negative impact on neurocognitive function (NF) and quality of life (QOL). The
      aim of this review was to assess the impact of PCI on disease-specific and NF and
      QOL outcomes. MATERIALS AND METHODS: An electronic database literature search was
      completed to identify relevant studies. RESULTS: Fourteen published articles were
      included. PCI significantly reduced the incidence of BM, but no significant
      survival advantage was found. NF decline was reported in one trial. No
      significant difference in QOL with PCI was reported. PCI was well tolerated by
      the majority of patients with NSCLC and associated with a relatively low
      toxicity. CONCLUSION: PCI reduces the incidence of BM without any significant
      survival advantage. PCI has the potential to be beneficial in practice for
      certain patients with locally advanced NSCLC, based on disease factors and
      patient preference.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Precival, Crystalrose
AU  - Precival C
AD  - Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity
      College Dublin, Dublin, Ireland.
FAU - Landy, Mickayla
AU  - Landy M
AD  - Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity
      College Dublin, Dublin, Ireland.
FAU - Poole, Claire
AU  - Poole C
AD  - Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity
      College Dublin, Dublin, Ireland.
FAU - Mullaney, Laura
AU  - Mullaney L
AD  - Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, Trinity
      College Dublin, Dublin, Ireland [email protected]
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Brain Neoplasms/*prevention & control/secondary
MH  - Carcinoma, Non-Small-Cell Lung/pathology/*radiotherapy
MH  - *Cranial Irradiation
MH  - Humans
MH  - Lung Neoplasms/pathology/*radiotherapy
OTO - NOTNLM
OT  - Prophylactic cranial irradiation
OT  - disease-free survival
OT  - neurocognitive function
OT  - non-small cell lung cancer
OT  - overall survival
OT  - quality of life
OT  - review
EDAT- 2017/12/27 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/31 00:00 [received]
PHST- 2017/11/17 00:00 [revised]
PHST- 2017/11/23 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 38/1/7 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):7-14.